T-allo10 Cell Addback Post-Αβdepleted-HSCT Drives Lasting Leukemia-Free Survival with Distinct Immune Regulation Biomarkers

Key Points

• Leukemia-free survival improves significantly with T-allo10 cell addback after abdepleted-hsct.
• The analysis shows a marked increase in lasting leukemia-free survival reaching 80% at one year.
• Assessment using immune regulation biomarkers reveals distinct profiles after T-allo10 treatment.
• Implications suggest novel therapeutic strategies may enhance outcomes in leukemia treatment.